Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015370503> ?p ?o ?g. }
- W3015370503 endingPage "1677" @default.
- W3015370503 startingPage "1669" @default.
- W3015370503 abstract "The inexpensive, well-tolerated, immunomodulatory agent leflunomide, used extensively for the treatment of rheumatoid arthritis, has been shown to produce significant activity against multiple myeloma (MM) in pre-clinical studies. We conducted a phase 1 study (clinicaltrials.gov: NCT02509052) of single agent leflunomide in patients with relapsed/refractory MM (≥3 prior therapies). At dose levels 1 and 2 (20 and 40 mg), no dose-limiting toxicities (DLTs) were observed. At dose level 3 (60 mg), one patient experienced elevated alanine aminotransferase; an additional three patients were enrolled at this dose level without further DLTs. Overall, toxicities were infrequent and manageable. Nine out of 11 patients achieved stable disease (SD), two subjects experiencing SD for nearly one year or longer. The tolerable safety profile of leflunomide, combined with a potential disease stabilization, is motivating future studies of leflunomide, in combination with other MM drugs, or as an approach to delay progression of smoldering MM." @default.
- W3015370503 created "2020-04-17" @default.
- W3015370503 creator A5003439933 @default.
- W3015370503 creator A5004910687 @default.
- W3015370503 creator A5006711911 @default.
- W3015370503 creator A5013186731 @default.
- W3015370503 creator A5013430443 @default.
- W3015370503 creator A5014173403 @default.
- W3015370503 creator A5020037320 @default.
- W3015370503 creator A5022766377 @default.
- W3015370503 creator A5024461673 @default.
- W3015370503 creator A5026632776 @default.
- W3015370503 creator A5033267787 @default.
- W3015370503 creator A5035985145 @default.
- W3015370503 creator A5039374832 @default.
- W3015370503 creator A5040738036 @default.
- W3015370503 creator A5046080795 @default.
- W3015370503 creator A5046351026 @default.
- W3015370503 creator A5048042606 @default.
- W3015370503 creator A5079132331 @default.
- W3015370503 creator A5087822741 @default.
- W3015370503 date "2020-04-08" @default.
- W3015370503 modified "2023-09-30" @default.
- W3015370503 title "Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study" @default.
- W3015370503 cites W1964309870 @default.
- W3015370503 cites W1966875430 @default.
- W3015370503 cites W1976002972 @default.
- W3015370503 cites W1978889996 @default.
- W3015370503 cites W1981690748 @default.
- W3015370503 cites W1999964913 @default.
- W3015370503 cites W2000130439 @default.
- W3015370503 cites W2009802594 @default.
- W3015370503 cites W2012843756 @default.
- W3015370503 cites W2056206654 @default.
- W3015370503 cites W2060496777 @default.
- W3015370503 cites W2066800926 @default.
- W3015370503 cites W2074354044 @default.
- W3015370503 cites W2076393800 @default.
- W3015370503 cites W2097043422 @default.
- W3015370503 cites W2102181111 @default.
- W3015370503 cites W2104438003 @default.
- W3015370503 cites W2124154590 @default.
- W3015370503 cites W2131015323 @default.
- W3015370503 cites W2133268402 @default.
- W3015370503 cites W2133708837 @default.
- W3015370503 cites W2144930991 @default.
- W3015370503 cites W2146784451 @default.
- W3015370503 cites W2154147815 @default.
- W3015370503 cites W2160699404 @default.
- W3015370503 cites W2166996710 @default.
- W3015370503 cites W2201190784 @default.
- W3015370503 cites W2228301361 @default.
- W3015370503 cites W2625253716 @default.
- W3015370503 cites W2808202754 @default.
- W3015370503 cites W2904768589 @default.
- W3015370503 cites W2921533600 @default.
- W3015370503 cites W2929868087 @default.
- W3015370503 cites W2947341253 @default.
- W3015370503 cites W2981617674 @default.
- W3015370503 cites W4206805253 @default.
- W3015370503 cites W4229960078 @default.
- W3015370503 cites W88786743 @default.
- W3015370503 doi "https://doi.org/10.1080/10428194.2020.1742900" @default.
- W3015370503 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7384948" @default.
- W3015370503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32268821" @default.
- W3015370503 hasPublicationYear "2020" @default.
- W3015370503 type Work @default.
- W3015370503 sameAs 3015370503 @default.
- W3015370503 citedByCount "14" @default.
- W3015370503 countsByYear W30153705032021 @default.
- W3015370503 countsByYear W30153705032022 @default.
- W3015370503 countsByYear W30153705032023 @default.
- W3015370503 crossrefType "journal-article" @default.
- W3015370503 hasAuthorship W3015370503A5003439933 @default.
- W3015370503 hasAuthorship W3015370503A5004910687 @default.
- W3015370503 hasAuthorship W3015370503A5006711911 @default.
- W3015370503 hasAuthorship W3015370503A5013186731 @default.
- W3015370503 hasAuthorship W3015370503A5013430443 @default.
- W3015370503 hasAuthorship W3015370503A5014173403 @default.
- W3015370503 hasAuthorship W3015370503A5020037320 @default.
- W3015370503 hasAuthorship W3015370503A5022766377 @default.
- W3015370503 hasAuthorship W3015370503A5024461673 @default.
- W3015370503 hasAuthorship W3015370503A5026632776 @default.
- W3015370503 hasAuthorship W3015370503A5033267787 @default.
- W3015370503 hasAuthorship W3015370503A5035985145 @default.
- W3015370503 hasAuthorship W3015370503A5039374832 @default.
- W3015370503 hasAuthorship W3015370503A5040738036 @default.
- W3015370503 hasAuthorship W3015370503A5046080795 @default.
- W3015370503 hasAuthorship W3015370503A5046351026 @default.
- W3015370503 hasAuthorship W3015370503A5048042606 @default.
- W3015370503 hasAuthorship W3015370503A5079132331 @default.
- W3015370503 hasAuthorship W3015370503A5087822741 @default.
- W3015370503 hasBestOaLocation W30153705032 @default.
- W3015370503 hasConcept C121332964 @default.
- W3015370503 hasConcept C126322002 @default.
- W3015370503 hasConcept C142424586 @default.
- W3015370503 hasConcept C143998085 @default.
- W3015370503 hasConcept C203014093 @default.